Cargando…

Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma

Objective. The aim of this study was to evaluate the combined effects of MMP-2 and TIMP-2 protein immunoreactivities on the prognosis in endometrial carcinoma. Methods. Paraffin-embedded tissue samples from 225 primary endometrioid adenocarcinomas and 13 histologies other than endometrioid adenocarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Honkavuori-Toivola, Maria, Santala, Markku, Soini, Ylermi, Turpeenniemi-Hujanen, Taina, Talvensaari-Mattila, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810671/
https://www.ncbi.nlm.nih.gov/pubmed/24344400
http://dx.doi.org/10.1155/2013/416870
_version_ 1782288832644775936
author Honkavuori-Toivola, Maria
Santala, Markku
Soini, Ylermi
Turpeenniemi-Hujanen, Taina
Talvensaari-Mattila, Anne
author_facet Honkavuori-Toivola, Maria
Santala, Markku
Soini, Ylermi
Turpeenniemi-Hujanen, Taina
Talvensaari-Mattila, Anne
author_sort Honkavuori-Toivola, Maria
collection PubMed
description Objective. The aim of this study was to evaluate the combined effects of MMP-2 and TIMP-2 protein immunoreactivities on the prognosis in endometrial carcinoma. Methods. Paraffin-embedded tissue samples from 225 primary endometrioid adenocarcinomas and 13 histologies other than endometrioid adenocarcinoma were immunohistochemically stained for MMP-2 and TIMP-2. Results. In Kaplan-Meier analysis, the 5-year cancer-specific survival rate of the endometrioid adenocarcinoma patients with negative MMP-2 and positive TIMP-2 staining was 100%, whereas only 78% of patients presenting with positive MMP-2 and negative TIMP-2 staining results were alive at that time. In Cox regression analysis, patients with positive MMP-2 and negative TIMP-2 immunostaining had a 4.7-fold relative risk of death from endometrial carcinoma compared to the group of patients with negative MMP-2 and positive or negative TIMP-2 immunoreaction. Conclusions. MMP-2 seems to be the main metalloproteinase determining the prognosis in endometrial carcinoma. Combination of strong MMP-2 and weak TIMP-2 immunostainings was the most potent prognostic marker for poor survival.
format Online
Article
Text
id pubmed-3810671
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-38106712013-12-10 Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma Honkavuori-Toivola, Maria Santala, Markku Soini, Ylermi Turpeenniemi-Hujanen, Taina Talvensaari-Mattila, Anne Dis Markers Research Article Objective. The aim of this study was to evaluate the combined effects of MMP-2 and TIMP-2 protein immunoreactivities on the prognosis in endometrial carcinoma. Methods. Paraffin-embedded tissue samples from 225 primary endometrioid adenocarcinomas and 13 histologies other than endometrioid adenocarcinoma were immunohistochemically stained for MMP-2 and TIMP-2. Results. In Kaplan-Meier analysis, the 5-year cancer-specific survival rate of the endometrioid adenocarcinoma patients with negative MMP-2 and positive TIMP-2 staining was 100%, whereas only 78% of patients presenting with positive MMP-2 and negative TIMP-2 staining results were alive at that time. In Cox regression analysis, patients with positive MMP-2 and negative TIMP-2 immunostaining had a 4.7-fold relative risk of death from endometrial carcinoma compared to the group of patients with negative MMP-2 and positive or negative TIMP-2 immunoreaction. Conclusions. MMP-2 seems to be the main metalloproteinase determining the prognosis in endometrial carcinoma. Combination of strong MMP-2 and weak TIMP-2 immunostainings was the most potent prognostic marker for poor survival. Hindawi Publishing Corporation 2013 2013-09-11 /pmc/articles/PMC3810671/ /pubmed/24344400 http://dx.doi.org/10.1155/2013/416870 Text en Copyright © 2013 Maria Honkavuori-Toivola et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Honkavuori-Toivola, Maria
Santala, Markku
Soini, Ylermi
Turpeenniemi-Hujanen, Taina
Talvensaari-Mattila, Anne
Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title_full Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title_fullStr Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title_full_unstemmed Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title_short Combination of Strong MMP-2 and Weak TIMP-2 Immunostainings Is a Significant Prognostic Factor in Endometrial Carcinoma
title_sort combination of strong mmp-2 and weak timp-2 immunostainings is a significant prognostic factor in endometrial carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3810671/
https://www.ncbi.nlm.nih.gov/pubmed/24344400
http://dx.doi.org/10.1155/2013/416870
work_keys_str_mv AT honkavuoritoivolamaria combinationofstrongmmp2andweaktimp2immunostainingsisasignificantprognosticfactorinendometrialcarcinoma
AT santalamarkku combinationofstrongmmp2andweaktimp2immunostainingsisasignificantprognosticfactorinendometrialcarcinoma
AT soiniylermi combinationofstrongmmp2andweaktimp2immunostainingsisasignificantprognosticfactorinendometrialcarcinoma
AT turpeenniemihujanentaina combinationofstrongmmp2andweaktimp2immunostainingsisasignificantprognosticfactorinendometrialcarcinoma
AT talvensaarimattilaanne combinationofstrongmmp2andweaktimp2immunostainingsisasignificantprognosticfactorinendometrialcarcinoma